Common Side Effects Patients Experience Over Time
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows upper respiratory infections as the most frequent side effect in long-term studies, affecting up to 15-20% of patients after years of use.[1][2] Diarrhea and oral herpes also persist in 5-10% of cases beyond the first year.
Serious Long-Term Risks Like Infections
Patients on Cosentyx face heightened infection risks that can worsen over time, including tuberculosis reactivation (rare but monitored via screening) and invasive fungal infections like candidiasis.[1][3] Long-term data from extension trials (up to 5 years) report serious infections in 2-5% of users, with rates stable but cumulative.[2]
Inflammatory Bowel Disease Concerns
New-onset or worsening Crohn's disease or ulcerative colitis emerges as a key long-term risk, with post-marketing reports in 0.1-1% of patients after 1-2 years.[1][4] Novartis warns of this in labeling, advising monitoring for GI symptoms.
Malignancy and Cancer Watch
No definitive causal link to cancer, but long-term registries (e.g., 5+ years) track slightly elevated rates of non-melanoma skin cancers (1-2 per 100 patient-years), similar to other biologics.[2][5] Patients with prior malignancy history need closer surveillance.
How Long-Term Safety Data Was Gathered
Safety profiles draw from phase 3 trials (e.g., FUTURE and MEASURE studies) extended up to 5 years, plus real-world registries like SCULPTURE showing consistent risks without major new signals.[2][3] No 10+ year data yet, as approval was in 2015.
What Happens If Side Effects Develop Long-Term
Discontinuation reverses most risks like infections within months, but IBD flares may persist.[1][4] Patients report fatigue and injection-site reactions fading after 6-12 months, per user forums and registries.[5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: 5-Year Safety Data from Secukinumab Trials (PubMed)
[3]: FDA Label Updates on Infections
[4]: Post-Marketing IBD Reports (EMA)
[5]: Psoriasis Longitudinal Assessment Registry (PubMed)